[1] 全国儿科哮喘协作组.中国儿童哮喘患病情况调查[N].中国医学论坛报,2006.4.27.
[2] Hopp RJ,Bewtra AK,Watt GD.Genetic analysis of allergic disease in twins[J].J Allergy Clin Immunol,1984,73:265-270.
[3] Prieto J,Lensmar C,Roquet A,et al.Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations[J].Respir Med,2000,94:806-814.
[4] Konstantinidis AK,Barton SJ,Sayers I,et al.Genetic association studies of interleukin-13 receptor alpha1 subunit gene polymorphisms in asthma and atopy[J].Eur Respir J,2007,30:40-47.
[5] Pope SM,Brandt EB,Mishra A,et al.IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxindependent mechanism[J].J Allergy Clin Immunol,2001,108:594-601.
[6] Chibana K,Trudeau JB,Mustovich AT,et al.IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells[J].Clin Exp Allergy,2008,38:936-946.
[7] Martinez-Nunez RT,Louafi F,Sanchez-Elsner T.The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1)[J].J Biol Chem,2011,286:1786-1794.
[8] Taussig LM,Wright AL,Holberg CJ,et al.Tucson children s spiratory study:1980 to present[J].J Allergy Clin Immunol,2003,111(4):661-675.
[9] 王长征.支气管哮喘表型[J].内科理论与实践,2011,6(2):102-105.
[10] Kurukulaaratchy RJ,Fenn MH,Waterhouse LM,et al.Characterization of wheezing phenotypes in the first 10years of life[J].Clin Exp Allergy,2003,33(5):573-578.
[11] Kelly C,Theresa WG.Pediatric asthma phenotypes[J].Curr Opin Pediatr,2012,24:344-351.
[12] 赵锰,赵京,戴耀华.哮喘基因进展[J].中华临床免疫和变态反应杂志,2009,3(2):122-127.
[13] Nie W,Liu YA,Bian JR,et al.Effects of polymorphisms-1112C/T and +2044A/G in interleukin-13 gene on asthma risk:a Meta-analysis[J].PloS One,2013,8(2):e56065.
[14] Micheal S,Minhas K,Ishaque M,et al.IL-13 Gene Polymorphisms and their association with atopic asthma and rhinitis in pakistani patients[J].Iran J Allergy Asthma Immunol,2013,12(4):391-396.
[15] Beghé B,Hall IP,Parker SG,et al.Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease[J].Allergy,2010,65:474-481.
[16] Gwan GS,Young HL.Pathway analysis of genome-wide association study on asthma[J].Human Immunology,2013,74(2):256-260.
[17] Hiromi N,Yutaka N,Hiroyuki K,et al.Effect of genetic variation of IL-13 on airway remodeling in bronchial asthma[J].Allergology International,2011,60:291-298.
[18] 谢莉,李艳,刘蓉,等.孟鲁司特钠治疗儿童咳嗽变异性哮喘 45 例疗效观察[J].药物与临床,2012,50(28):52-53.
[19] 楼英萍.孟鲁司特钠治疗儿童咳嗽变异性哮喘的疗效观察[J].海峡药学,2011,23(5):157-158.
[20] Gary MH,Manuel ES,Lydiana A,et al.Polymorphisms in IL13,total IgE,eosinophilia,and asthma exacerbations in childhood[J].J Allergy Clin Immunol,2007,120:84-90.
[21] Jonathan C,Robert FL,Nicola AH,et al.Lebrikizumab treatment in adults with asthma[J].N Engl J Med,2011,365:1088-1098.
[22] Jonathan C.Role of interleukin-13 in asthma[J].Curr Allergy Ashma Rep,2013,13(5):415-420.
[23] Piper E,Brightling C,Niven R,et al.A phase II placebocontrolled study of tralokinumab in moderate-to-severe asthma[J].European Respiratory,2013,41(2):330-338.
[24] Wechsler ME,Kunselman SJ,Chinchilli VM,et al.Effect of beta 2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial):a genotypestratified,randomised,placebo-controlled,crossover trial[J].Lancet,2009,374:1754-1764.
[25] Israel E,Chinchilli VM,Ford JG,et al.Use of regularly scheduled albuterol treatment in asthma:genotype-stratified,randomised,placebo-controlled cross-over trial[J].Lancet,2004,364:1505 -1512.
[26] Slager RE,Otulana BA,Hawkins GA,et al.IL-4 receptor polymorphisms predict reduction in asthma exacerbationsduring response to an anti-IL-4 receptor alpha antagonist[J].J Allergy Clin Immunol,2012,130:516 -522.